INDEX TO VOLUME 172

Author Index

Abbud, R. A., 859
Aboulker, J. P., 656
Abrams, E. J., 353
Abrams, J., 1084
Abranches, P., 323
Ackerman, S. K., 161
Adams, J. M., 1126
Adrien, M., 764
Afghani, B., 903
Aguado, J. M., 608
Aguiniga, E., 70
Åhman, H., 1273
AIDS Clinical Trials Group 213 Team, 1246
AIDS Clinical Trials Group 143 Virology Team, 70
Akagi, S., 1191
Aledort, L. M., 228
Alley, E. S., 204
Alls, S., 1167
Allsup, A., 1290
Alper, C. M., 1348
An, D. D., 88
Anaissie, E. J., 599
Andersen, P. L., 497
Anderson, B. E., 1528
Anderson, E. L., 1445
Anderson, K., 1348
Anderson, L. J., 1076, 1206
Andrew, P. W., 119
Angeloni, A., 1367
Ank, B. J., 1492
Antinori, S., 901
Araujo, E., 831
Arbeter, A., 217
Arden, N. H., 246
Arduino, M. J., 993
Arevalo, J. F., 951
Armentor, B. S., 446
Armstrong, L. R., 1166
Aroda, V. R., 1492
Arribas, J. R., 527
Arvin, A., 217
Asgari, M., 1634
Ashman, R. B., 823
Ashworth, L. A. E., 1261
Asmuth, D. M., 1317
Atkinson, R., 1567
Atmadja, A. K., 1567
Atmar, R. L., 253
Atzori, C., 1623
Augenbraun, M., 235
Augustine, N. H., 1608
Ausiello, C. M., 211
Autenrieth, I. B., 490
Auvergnat, J.-C., 258
Avonts, D., 551
Azmi, F. H., 1279
Bachelez, H., 672
Back, D. J., 1634
Backman, A., 574
Bahraoui, E., 672
Bailey, A. S., 629
Bailey, R. L., 268
Bakken, J. S., 1007, 1141
Balaban, N., 845
Balducci, M., 1169
Bales, J. D., 1047
Balfe, P., 1080
Balish, E., 1612, 192
Bamji, M., 353
Banerjee, S., 993
Banya, W. A. S., 316
Baranton, G., 281
Barg, N. L., 410
Barie, P. S., 577
Barker, W. H., 389
Barlough, J. E., 1141
Baron, R. C., 817
Barrera-Oro, M., 1126
Barrett, T. J., 1122
Bartelink, A. K. M., 433
Barthold, S. W., 286, 778
Bartlett, M. S., 1623
Baskin, G. B., 535
Bates, J., 983
Battjes, R. J., 51
Bauer, H. M., 895
Bauer, R., 144
Baughman, R. P., 595
Baumgartner, P., 395
Bayer, W. L., 1076
Beadle, C., 1047
Beattie, D. T., 1126
Beaulieu, B. L., 739
Beaumont, C., 983
Beck-Sague, C., 1542
Behets, F. M.-T., 764
Beier, J. C., 1047
Beier, P. L., 919
Bélec, L., 691
Bellesia, E., 105
Belshe, R. B., 1445
Benhamou, Y., 622
Bennett, C. L., 312
Bennett, S., 316
Berger, M., 453
Bergeron-Lynn, G., 951
Bernard, G. R., 1119
Bernard, H.-U., 895
Bernatowicz, A., 113
Bernstein, D. I., 944
Bernstein, H., 217
Bertrand, J.-C., 607, 1171
Bessen, D. E., 1608
Betts, R. F., 389
Bhattacharyya, C., 785
Bindels, P. J. E., 97
Blake, C., 1028
Blanchard, A., 672
Bland, L. A., 993
Blanshard, C., 622
Blatt, S. P., 79
Blatter, M., 217
Blattner, W. A., 51, 867
Blauw, B., 535
Bliska, J., 1290
Bloch, C., 1536
Blomberg, J., 682
Blomme, W., 1298
Bloom, B. R., 698
Blumberg, B. S., 713
Blumberg, H. M., 1542
Boatin, B. A., 204
Bockenstedt, L. K., 286
Bodey, G. P., 599
Bodley, A. L., 1157
Boeckh, M., 939
Bohn, E., 490
Bolan, G., 1013, 1411
Bolitho, E. M., 823
Bollinger, R. C., 1486
Bonneux, L., 204
Bonville, C. A., 389
Bórdon, J., 905
Borghi, V., 105
Bosch, F. X., 19
Boslego, J. W., 180, 186
Bosso, J., 599
Boswell, R. N., 79
Boulianne, N., 1591
Boulnois, G. J., 119
Boulos, R., 764
Bourderioux, C., 258
Bourgeois, E., 672
Bourne, N., 944
Bow, L. M., 810
Bowden, R. A., 939
Boyce, T. G., 1401
Bradley, J. E., 831
Brander, E., 574
Brandt, C. A., 124
Bratcher, D. F., 944
Brattegaard, K., 1371
Bravo, F. J., 944
Breiman, R. F., 729
Briggs, M., 1080
Briggs, N. C., 51
Brink, N. S., 1087
Britt, W. J., 1212
Brookmeyer, R. S., 1486
Brouwers, P., 638
Brown, A. E., 1091
Brown, C. S., 1431
Brown, J., 1145
Bruczak, J. D., 1411
Brummer, E., 1620
Brundage, J. F., 124
Brunet, C. M., 1324
Bryant, A. E., 1317
Bryson, Y. J., 359
Buchman, C. A., 1348
Buckland, J., 1425
Bucklin, S. E., 1519
Buckner, C. D., 939
Burakova, T., 25
Burke, J. F., 308
Busch, M. P., 648
Butzler, J.-P., 1298
Buurman, W. A., 577
Bwayo, J., 1469
Byrne, C., 1384
Calvopiña, M., 831
Cameron, D. N., 173
Campbell, G. L., 470
Campbell, L. A., 585, 593
Campbell, M. J., 1
Cantey, J. R., 136
Cantor, K. P., 51
Canvin, J. R., 119
Capparelli, E. V., 951
Cappuccio, A. L., 585
Carbon, C., 1312
Cargnel, A., 1623
Carson, P. J., 340
Carter, J. J., 11
Carter-Campbell, S., 723
Cartter, M. L., 570
Cartwright, C. P., 1638
Cassai, E., 1605
Cate, T. R., 253
Cavalli, B., 1595
Cerisier, J.-E., 258
Chadwick, E. G., 1475
Chaisson, R. E., 346
Chambers, G. W., 1
Chan, L., 927
Chan, S.-Y., 895
Chandramuki, A., 301
Chandrasekaran, V., 1616
Chanock, S., 1028
Chao, C. C., 1137
Chapman, N. M., 1212
Chapnick, E. K., 1423
Chappell, C. L., 1170
Chargelegue, D., 897
Charpentier, E., 277
Chartrand, S., 217
Chatterjee, D., 1137
Chehadeh, H., 1598
Chen, C.-H., 964
Chen, D.-S., 261
Chen, P.-J., 261
Cheng, G., 1584
Cheung, P., 927
Chiang, S. C., 891

INDEX TO VOLUME 172

Author Index

Abbud, R. A., 859
Aboulker, J. P., 656
Abrams, E. J., 353
Abrams, J., 1084
Abranches, P., 323
Ackerman, S. K., 161
Adams, J. M., 1126
Adrien, M., 764
Afghani, B., 903
Aguado, J. M., 608
Aguiniga, E., 70
Åhman, H., 1273
AIDS Clinical Trials Group 213 Team, 1246
AIDS Clinical Trials Group 143 Virology Team, 70
Akagi, S., 1191
Aledort, L. M., 228
Alley, E. S., 204
Alls, S., 1167
Allsup, A., 1290
Alper, C. M., 1348
An, D. D., 88
Anaissie, E. J., 599
Andersen, P. L., 497
Anderson, B. E., 1528
Anderson, E. L., 1445
Anderson, K., 1348
Anderson, L. J., 1076, 1206
Andrew, P. W., 119
Angeloni, A., 1367
Ank, B. J., 1492
Antinori, S., 901
Araujo, E., 831
Arbeter, A., 217
Arden, N. H., 246
Arduino, M. J., 993
Arevalo, J. F., 951
Armentor, B. S., 446
Armstrong, L. R., 1166
Aroda, V. R., 1492
Arribas, J. R., 527
Arvin, A., 217
Asgari, M., 1634
Ashman, R. B., 823
Ashworth, L. A. E., 1261
Asmuth, D. M., 1317
Atkinson, R., 1567
Atmadja, A. K., 1567
Atmar, R. L., 253
Atzori, C., 1623
Augenbraun, M., 235
Augustine, N. H., 1608
Ausiello, C. M., 211
Autenrieth, I. B., 490
Auvergnat, J.-C., 258
Avonts, D., 551
Azmi, F. H., 1279
Bachelez, H., 672
Back, D. J., 1634
Backman, A., 574
Bahraoui, E., 672
Bailey, A. S., 629
Bailey, R. L., 268
Bakken, J. S., 1007, 1141
Balaban, N., 845
Balducci, M., 1169
Bales, J. D., 1047
Balfe, P., 1080
Balish, E., 1612, 192
Bamji, M., 353
Banerjee, S., 993
Banya, W. A. S., 316
Baranton, G., 281
Barg, N. L., 410
Barie, P. S., 577
Barker, W. H., 389
Barlough, J. E., 1141
Baron, R. C., 817
Barrera-Oro, M., 1126
Barrett, T. J., 1122
Bartelink, A. K. M., 433
Barthold, S. W., 286, 778
Bartlett, M. S., 1623
Baskin, G. B., 535
Bates, J., 983
Battjes, R. J., 51
Bauer, H. M., 895
Bauer, R., 144
Baughman, R. P., 595
Baumgartner, P., 395
Bayer, W. L., 1076
Beadle, C., 1047
Beattie, D. T., 1126
Beaulieu, B. L., 739
Beaumont, C., 983
Beck-Sague, C., 1542
Behets, F. M.-T., 764
Beier, J. C., 1047
Beier, P. L., 919
Bélec, L., 691
Bellesia, E., 105
Belshe, R. B., 1445
Benhamou, Y., 622
Bennett, C. L., 312
Bennett, S., 316
Berger, M., 453
Bergeron-Lynn, G., 951
Bernard, G. R., 1119
Bernard, H.-U., 895
Bernatowicz, A., 113
Bernstein, D. I., 944
Bernstein, H., 217
Bertrand, J.-C., 607, 1171
Bessen, D. E., 1608
Betts, R. F., 389
Bhattacharyya, C., 785
Bindels, P. J. E., 97
Blake, C., 1028
Blanchard, A., 672
Bland, L. A., 993
Blanshard, C., 622
Blatt, S. P., 79
Blatter, M., 217
Blattner, W. A., 51, 867
Blauw, B., 535
Bliska, J., 1290
Bloch, C., 1536
Blomberg, J., 682
Blomme, W., 1298
Bloom, B. R., 698
Blumberg, B. S., 713
Blumberg, H. M., 1542
Boatin, B. A., 204
Bockenstedt, L. K., 286
Bodey, G. P., 599
Bodley, A. L., 1157
Boeckh, M., 939
Bohn, E., 490
Bolan, G., 1013, 1411
Bolitho, E. M., 823
Bollinger, R. C., 1486
Bonneux, L., 204
Bonville, C. A., 389
Bórdon, J., 905
Borghi, V., 105
Bosch, F. X., 19
Boslego, J. W., 180, 186
Bosso, J., 599
Boswell, R. N., 79
Boulianne, N., 1591
Boulnois, G. J., 119
Boulos, R., 764
Bourderioux, C., 258
Bourgeois, E., 672
Bourne, N., 944
Bow, L. M., 810
Bowden, R. A., 939
Boyce, T. G., 1401
Bradley, J. E., 831
Brander, E., 574
Brandt, C. A., 124
Bratcher, D. F., 944
Brattegaard, K., 1371
Bravo, F. J., 944
Breiman, R. F., 729
Briggs, M., 1080
Briggs, N. C., 51
Brink, N. S., 1087
Britt, W. J., 1212
Brookmeyer, R. S., 1486
Brouwers, P., 638
Brown, A. E., 1091
Brown, C. S., 1431
Brown, J., 1145
Bruczak, J. D., 1411
Brummer, E., 1620
Brundage, J. F., 124
Brunet, C. M., 1324
Bryant, A. E., 1317
Bryson, Y. J., 359
Buchman, C. A., 1348
Buckland, J., 1425
Bucklin, S. E., 1519
Buckner, C. D., 939
Burakova, T., 25
Burke, J. F., 308
Busch, M. P., 648
Butzler, J.-P., 1298
Buurman, W. A., 577
Bwayo, J., 1469
Byrne, C., 1384
Calvopiña, M., 831
Cameron, D. N., 173
Campbell, G. L., 470
Campbell, L. A., 585, 593
Campbell, M. J., 1
Cantey, J. R., 136
Cantor, K. P., 51
Canvin, J. R., 119
Capparelli, E. V., 951
Cappuccio, A. L., 585
Carbon, C., 1312
Cargnel, A., 1623
Carson, P. J., 340
Carter, J. J., 11
Carter-Campbell, S., 723
Cartter, M. L., 570
Cartwright, C. P., 1638
Cassai, E., 1605
Cate, T. R., 253
Cavalli, B., 1595
Cerisier, J.-E., 258
Chadwick, E. G., 1475
Chaisson, R. E., 346
Chambers, G. W., 1
Chan, L., 927
Chan, S.-Y., 895
Chandramuki, A., 301
Chandrasekaran, V., 1616
Chanock, S., 1028
Chao, C. C., 1137
Chapman, N. M., 1212
Chapnick, E. K., 1423
Chappell, C. L., 1170
Chargelegue, D., 897
Charpentier, E., 277
Chartrand, S., 217
Chatterjee, D., 1137
Chehadeh, H., 1598
Chen, C.-H., 964
Chen, D.-S., 261
Chen, P.-J., 261
Cheng, G., 1584
Cheung, P., 927
Chiang, S. C., 891

Chidiac, C., 656
Childs, J. E., 462
Chirgwin, K. D., 235
Choi, H., 1554
Choo, P. W., 706
Chou, S., 239
Chowdhury, A., 1191
Christensen, N. D., 395
Christin, L., 1153
Chu, Y.-K., 1581
Chumo, D. K., 1047
Chung, R. C.-Y., 1091
Chytil, F., 1167
Cimolai, N., 293
Cirioni, O., 1169
Clark, B. D., 308
Clauvel, J.-P., 672
Clayson, E. T., 927
Clement, C., 608
Clements, D., 217
Clements, M. L., 1445
Clerici, M., 79
Clifford, D. B., 527
Clumeck, N., 1253
Cochereau, I., 1312
Coffin, S. E., 874
Cohen, A. R., 228
Cohen, M. S., 764
Cohn, S. E., 312
Coicou, G., 764
Colebunders, R., 551
Coligan, J. E., 554
Colvin, B. T., 897
Commins, D. L., 527
Comstock, L., 883
Conley, E., 1364
Connor, J. D., 951
Cook, R. W., 1261
Cooling, L. L. W., 1198
Cooper, D. A., 1384
Cooper, J., 1145
Corallini, A., 1605
Cossarizza, A., 105
Costa, M. C., 756
Coster, T. S., 1126
Couch, R. B., 253
Couillard, M., 1591
Courvalin, P., 277
Coutinho, R. A., 97
Cover, T. L., 290
Cox, N. J., 1352
Coyle, S. M., 577
Craft, J. E., 1324
Cranage, M. P., 1261
Craven, R. B., 470
Crawford, J. T., 1542
Cretella, S., 1324
Crisp, C., 427
Cross, A. S., 180, 186
Crowley, J. S., 638
Crusiaux, A., 1253
Cruz-Ruiz, M., 581
Cummings, P. K., 585
Cunningham, C. K., 389
Dahmer, L. A., 1612
Dale, D. C., 1061
Daley, C. L., 566
Daley, G. G., 531
Daling, J. R., 11
Dallabetta, G., 764
Dalton, M. J., 729
Dankert, J., 1388
Dankert-Roelse, J. E., 1388
Dapunt, O., 395
D'Aquila, R. T., 88
d'Arminio Monforte, A., 901
Darnell, M. E. R., 243
Dash, R., 682
Datta, P., 1419
Davis, H., 764
Davis, J. P., 1122
Deal, C. D., 180, 186
Dean, D., 1013
de Béthune, M.-P., 380
De Caluwé, P., 1336
De Clercq, E., 380
De Cock, K. M., 1371
de Dennis, S. R. K., 1475
Dedet, J. P., 323
Deelder, A. M., 1336
DeHovitz, J. A., 312
de Jong, J. C., 629
Dekker, B. A. T., 562
Delaney, S. F., 1384
de Leij, L., 879
de Lellis, L., 1605
Delius, H., 895
Del Prete, M. S., 1169
De Maddalena, C., 1595
Demers, G. W., 747
Demeter, L. M., 1480
Demko, C. A., 453
Deniau, M., 323
Dennehy, P. H., 45
Dennis, D. T., 470
Dennis, M. J., 1261
Dereure, J., 323
De Rienzo, B., 105
de Sanjosé, S., 19
De Serres, G., 1591
Desormeaux, J., 764
de Souza, M., 778
Detels, R., 329
Deveikis, A., 359
DeVelasco, E. A., 562
De Vlas, S. J., 204, 1336
Dexter, A., 1480
Dharmana, E., 305
Diallo, M. O., 1371
Diamond, R. D., 511, 1153
DiCarlo, R. P., 446
Dickinson, G. M., 312
Dietrich, S. L., 648
Dietrich, U., 682
Dinarello, C. A., 308
Distler, O., 1384
Divekar, A. D., 1486
Djokomoeljanto, R., 305
Dohin, E., 622
Dolan, M. J., 79
Dolin, R., 1175, 1480
Dolmans, W. M. V., 305
Donahue, J. G., 706
Donegan, E., 648
Dorrucci, M., 1503
Dowell, S. F., 1076
Doyle, W. J., 1348
Drenaggi, D., 1169
Drew, W. L., 239
Dryden, M., 1145
Duan, L.-X., 713
Duffy, L., 132
Dumler, J. S., 1007, 1141
Dumois, J. A., 232
Duncan, J. L., 1528
Dunn, D., 1418
Dupré, T., 691
Dynan, M., 88
Dytoc, M., 1393
Dytoc, M. T., 136
Eampokalap, B., 1405
Eberhard, M. L., 1630
Eberle, J., 1228
Edelman, R., 883
Edwards, M. S., 420
Ehrlich, G. D., 1348
Eibl, M. M., 1598
Eid, A., 25
Eiden, L. E., 59
Elgh, F., 1581
Ellerbrock, T., 898
Elson, L., 831
Embree, J. E., 1419
Emerson, S. U., 31
Emre, U., 265
Erdman, D. D., 1076
Erenberg, A. J. M., 144
Ermak, T. H., 161
Eskola, J., 1115, 1268, 1273
Espinoza, A. M., 794
Esposito, R., 901
Estes, M. K., 723
Ettiègne-Traoré, V., 1371
Evans, L. A., 1384
Evins, G. M., 173
Ewald, J. H., 490
Excler, J.-L., 258
Eyster, M. E., 228
Fabris, M., 1605
Faden, H., 132
Falck, L., 682
Falsey, A. R., 389
Farley, T. A., 246
Fasano, A., 1408
Feitelson, M. A., 713
Feldman, J., 235
Feldman, R. G., 562
Feng, S., 286
Fennelly, G. J., 698
Feo, C., 1605
Ferbas, J., 329
Ferrari, G., 964
Fichtenbaum, C. J., 527
Fikrig, E., 286, 1324
Fine, P. E. M., 543
Finegan, C. K., 859
Fireman, P., 1348
Fischer, E., 577
Fischetti, V. A., 1608
Flexner, C., 1246
Flynn, J. A. L., 698
Fontana, A., 113
Fontbonne, A., 656
Formal, S. B., 1408
Forthal, D. N., 1587
Fox, J. D., 1087
Foxman, B., 1536
Franceschi, C., 105
Franceschini, M. G., 105
Franchioly, P., 1253
Franco, E. L., 756
Frank, J. W., 1375
Fransen, K., 1228
Franzetti, F., 901
Freeman, C. Y., 1206
Freeman, T. M., 79
Freeman, W. R., 951
Frei, K., 113
Frenkel, L. M., 359
Friedland, I. R., 805
Friedmann, N., 144
Frieling, J. T. M., 608
Fukuda, R., 1191
Fukumoto, S., 1191
Fukunaga, N., 1306
Fukuyama, M., 558
Fulurija, A., 823
Furrer, H., 225
Furuta, Y., 1343
Gaffney, R. A., 1528
Galgiani, J. N., 199
Gallant, J. E., 346
Galli, M., 1595
Gallicano, K., 1635
Gallinella, G., 1360
Galloway, D. A., 11, 747
Galun, E., 25
Gambertoglio, J., 951
Gangakhedkar, R. R., 1486
Garcha, U. K., 1620
Garcia, R. F., 951
Garcia-Bravo, M., 608
Gårdlund, B., 296
Garner, J. A., 290
Gary, H. E., Jr., 1206
Gasem, M. H., 305
Gatermann, S., 1509
Gazzard, B. G., 622, 1087
Gelfand, J. A., 308
Gentilomi, G., 1360
Gentsch, J. R., 45
George, W. L., 312
Gérard, M., 1253
Gerbaud, G., 277
Gerberding, J. L., 1421
Gerding, M., 38

Gerondelis, P., 1480
Gery, P., 1171, 607
Ghys, P. D., 1371
Giacometti, A., 1169
Giercksky, K.-E., 152
Giesecke, J., 1135
Giesendorf, B. A. J., 1298
Gigase, P., 957
Gigler, A., 1356
Gilks, C., 983
Gillespie, B., 1536
Gilman, S. C., 312
Gilmore, M. S., 273
Gilquin, J., 611
Gilson, R. J. C., 1080
Ginsberg, R., 1246
Giono-Cerezo, S., 173
Giorgi, J. V., 329
Giraldo, G., 1605
Girard, D. D., 88
Glass, A. G., 1425
Glass, R. I., 45, 1437
Glaus, B., 1145
Gnaoré, E., 1371
Goedert, J. J., 51, 228
Goeman, J., 551
Goetz, M. B., 312
Gokhale, M. R., 1486
Goldman, M., 1253
Goldman, R., 845
Goldoft, M. J., 1166
Gómez-Jiménez, J., 1172
Gómez-Mateos, J., 581
Gonzalez, C., 951
Goodgame, R. W., 1170
Gooley, T. A., 939
Goossens, H., 1298
Gori, A., 901
Gorse, G. J., 1
Govorkova, E. A., 250
Gozlan, J., 1641
Graham, B. S., 734
Graham, N. M. H., 1168
Granoff, D. M., 1279
Grasselier, H., 1388
Grau, O., 672
Gray, R., 867
Grayston, J. T., 585, 593
Greenberg, A. E., 1371
Greenberg, M. L., 964
Greene, C., 1145
Greene, K. D., 173, 1122, 1401
Greene, R., 1145
Greer, C. E., 1425
Gregson, N. A., 605
Greiner, D. L., 974
Griffin, P. M., 1122
Groen, J., 38
Gryseels, B., 1336
Guaraldi, G., 105
Guay, L. A., 859
Gubareva, L. V., 250
Guderian, R., 831
Guelde, G., 794
Guentzel, S., 239
Guilliams, S. E., 723
Guinea, A., 521
Guiot, M.-C., 1591
Gunzenhauser, J. D., 124
Guo, J., 1554, 713
Guy, E. C., 319
Haas, D. W., 1167
Haas, W. H., 1542
Habbema, J. D. F., 204
Habel, L. A., 11
Habis, A., 1587
Hack, C. E., 144
Hackett, S. P., 1317
Hadler, J. L., 570
Haeffner-Cavaillon, N., 547
Haerden, Y., 551
Hagensee, M. E., 11
Hall, G. A., 1261
Haller, O., 365
Hamilton, D. H., 570
Hamilton, H. A., 764
Hamilton, J. D., 371, 531
Hammerschlag, M. R., 265
Hammill, H. A., 1451
Hampton, T. J., 268
Hamzeh, F. M., 1246
Han, C., 1584
Han, J., 1509
Hanicq, P., 1298
Hanscome, P. J., 1103
Hanson, I. C., 1451
Harmsen, M. C., 380, 879
Harrison, C. J., 1212
Harrison, T. S., 665
Harshman, S., 410
Hartard, C., 606
Hassan-King, M., 316
Hattori, N., 934
Haubrich, R. H., 1246
Hausner, M. A., 329
Havlir, D. V., 902, 1379
Hawkins, A. E., 1080
Hayashi, J., 1098
Hayden, F. G., 1348, 1352
Hayes, L. J., 268
Heagarty, M., 353
Hedman, K., 1431
Hedman, L., 1431
Hedrick, J., 1076
Heeney, J., 535, 957
Heesemann, J., 490
Heim, K., 395
Heinz, F. X., 1356
Helfand, R. F., 1206
Hemauer, A., 1356
Hemming, V. G., 243
Hendley, J. O., 772
Hendrix, C. W., 79
Hennessy, T., 729
Henry, S. C., 371, 531
Hensley, R., 79
Hernán, M. A., 353
Herrera, I., 723
Herva, E., 1330
Hesselton, R. M., 974
Heyes, M. P., 59, 638
Heyndrickx, L., 1228
Hickey, S., 805
Higgins, K. W., 539
Higgs, E., 1055
Hightower, A. W., 1630
Hilgartner, M. W., 228
Hill, H. R., 1608
Hill, J. E., 161
Hilton, E., 1616
Hinkle, C. J., 1076
Hirata, M., 1098
Hirsch, M. S., 88, 1246
Hirschel, B., 225
Hjelle, B., 1581
Ho, M., 838
Hockin, J. C., 1401
Hoepelman, A. I. M., 785
Hoepfl, R., 395
Hoffman, S. L., 1047
Hofheinz, D., 1091
Hofmeister, E. K., 462
Hofstra, H., 1298
Hollis, R. J., 772
Holmes, A., 1028
Holmes, K. K., 11, 747, 1461
Honda, T., 1405
Hooton, T. M., 440
Hoover, D. L., 186
Hopewell, P. C., 566
Hopkins, W. J., 1612
Horal, P., 1343
Horiike, N., 713
Horn, C. A., 1023
Horner, R. D., 312
Horowitz, I. R., 1184
Howe, D. K., 1561
Hoyi, Y. M., 1371
Hu, S., 1137
Hubbert, N. L., 19, 1425, 1584
Hufert, F. T., 365
Hughes, R. A. C., 605
Hughes, W. T., 506, 1042
Huls, C., 599
Hultin, L. E., 329
Hurren, L., 1384
Hutchinson, M. A., 1122
Huycke, M. M., 273
Hyman, T., 1126
Icenogle, J. P., 1184, 1584
Igarashi, H., 558
Iida, T., 1405
Ikematsu, H., 1098
Ilan, Y., 25
Imai, Y., 1306
Innis, B. L., 927
Irwin, K., 898
Isenberg, H. D., 1616
Ishibashi, M., 1405
Ishihara, S., 1191
Ishimura, N., 1191
Ishizaka, S. T., 1108
Ismaili, A., 136, 1393
Iversen, A. K. N., 70
Jackson, J. B., 228
Jackson, L., 723
Jacobson, J. M., 312
Jacquet, C., 277
Jadhav, V. D., 1486
Jameson, P., 1145
Janoff, E. N., 340, 566, 855, 1587
Jansen, J., 144
Janssens, W., 1228
Jarpe, A., 785
Jarvis, W. R., 817, 993, 1542
Javato-Laxer, M., 1587
Jehuda-Cohen, T., 1420
Jelonek, M. T., 539
Jenison, S., 1581
Jennings, C., 1221
Jennings, G., 1581
Jepson, A. P., 316
Jernigan, J., 1055
Jero, J., 1115
Jeronimo, S. M. B., 1055
Jiang, B., 1623, 45
Jiang, X., 1437
Johansson, B., 682
John, G. C., 1461
Johnson, R. P., 88
Johnson, S. A., 243
Jones, C., 1130
Jones, T. J., 603
Jones-Carson, J., 192
Jordans, H. G. M., 38
Jordens, J. Z., 983
Jorgensen, J. H., 427
Joseph, D., 764
Joyce, W. A., 273
Joynson, D. H. M., 319
Kabat, W., 558
Kahana, Y., 25
Kahn, J., 1637
Kaiser, L., 225
Kalams, S. A., 88
Kalé, K., 1371
Kamisawa, K., 1306
Kanerva, C., 1528
Kanga, J.-M., 691
Kao, J.-H., 261
Kaper, J. B., 883
Kaplan, A. H., 329
Kaplan, E. L., 124
Kaplan, S. L., 1001
Karl, C., 599
Karma, P., 1115
Karron, R. A., 1445
Kashiwagi, S., 1098
Katholi, C. R., 1414
Katila, M.-L., 574
Katlama, C., 622
Katz, D. A., 638
Katzenstein, D. A., 70
Kauppinen, M. T., 1330
Kaverin, N. V., 250

Käyhty, H., 1115, 1268, 1273
Kazatchkine, M. D., 547, 611
Keely, S. P., 595
Keitel, W. A., 253
Keller, M. A., 359, 539
Kenner, J. R., 1126
Kernodle, D. S., 410
Keruly, J., 346
Kessler, C. M., 228
Kessler, H. A., 312
Kestens, L., 957
Ketzinel, M., 25
Keuter, M., 305
Khabbaz, R. F., 1166
Khan, A. S., 1166
Khoo, S. H., 629
Khoury, C. A., 870
Kiger, K. P., 228
Killeen, K. P., 1126
Kimari, J., 983
Kimmings, A. N., 144
Kimsey, R. B., 1141
Kirnbauer, R., 19, 1425, 1584
Kirsch, L. S., 951
Kirste, G., 365
Kitchen, L. W., 1639
Kiviat, N. B., 11, 747
Kiyoshima, J., 403
Kjaer, S. K., 1584
Kleanthous, H., 161
Kleiner, D. E., 638
Klimov, A. I., 1352
Kline, M. W., 1451
Klinek, M., 874
Kluytmans, J. A. J. W., 1423
Koedel, U., 113
Koeken, A., 1298
Koeman, J. P., 38
Koener, T. A. W., 1198
Koenig, R. E., 1095
Kohara, M., 934
Kohge, N., 1191
Kohn, M. A., 246
Kolbert, C. P., 1007
Koles, N. L., 794
Komaroff, A. L., 1364
Konstan, M. W., 453
Kontoyiannis, D. P., 599
Kopp, J. B., 232
Kornfeld, H., 665
Korppi, M., 574
Koster, D. S., 1298
Kostman, J. R., 1638
Kouides, R. W., 389
Koutsky, L. A., 11, 747
Kozinetz, C. A., 1451
Krakauer, T., 988
Krasinski, K., 353
Krause, D. S., 1324
Kravitz, F. H., 1137
Kreider, J. W., 395
Kreiss, J. K., 1461, 1469
Krijger, F. W., 1336
Kröger, H., 574
Kröger, L., 574
Krol, A., 97
Kroner, B. L., 228
Krystofik, D. A., 132
Ksiazek, T. G., 729, 1166, 1581
Kubota, T., 220
Kuebler, D., 535
Kuijper, E. J., 886
Kujala, P., 1330
Kullberg, B.-J., 305
Kumar, M. L., 217
Kumar, P., 863
Kuo, C.-c., 585, 593
Kurikka, S., 1268
Kurman, R. J., 1425
Kurup, V., 1554
Kuschner, R. A., 180, 186
Kuypers, J., 11, 747
Kwok, S., 851
Lackner, A. A., 1149
Laczika, K., 1356
Lafeuillade, A., 672
Laga, M., 1371
Lahesmaa, R., 1290
Lai, M.-Y., 261
Lakey, D., 1167
Lal, R. B., 554
Lambert, G., 353
Lambrechts, A., 1253
Lammie, P. J., 1630
Lampe, M. F., 589
Landay, A. L., 1221
Landesman, S., 235
Landry, M. L., 1641
Landucci, G., 1587
Lane, J. R., 1091
Langston, C., 1451
Lantz, M., 301
Lasker, B. A., 817
Lau, J. Y. N., 934
Launay, V., 672
Launiala, K., 574
Laursen, A. L., 497
Lawoko, A., 682
Laxer, M., 1587
Leblanc, M., 1375
Lederman, M. M., 228, 1246
Lee, C.-H., 1623
Lee, C. K., 161
Lee, H., 648
Lee, H. H., 1411
Lee, H.-W., 1581
Lee, S.-K., 11
Lee, S. T., 891
Lefebvre, M., 323
Leinonen, M., 1115, 1330
Lepri, A. C., 1503
Lernestedt, J.-O., 622
Levine, M. M., 883, 1408
Levitz, S. M., 665, 1153
Lewis, D. E., 1451
Liao, F. M., 1408
Libin, M., 1253
Liebert, U. G., 698
Lietman, P., 1246
Liles, W. C., 1061, 1573
Lindemann, A., 610
Lindh, M., 1343
Lindkvist, P., 1135
Linke, M. J., 595
Linton, D., 1130
Liu, H. Y., 891
Liu, Z., 329
Livingston, D. J., 1238
Longfield, J. N., 124
Looareesuwan, S., 838
López-Cortés, L. F., 581
López-Galíndez, C., 1602
Lorenz, T. J., 144
Lorenzl, S., 113
Lorincz, A. T., 1425
Lorougnon, F., 1371
Losonsky, G., 883
Louise, C. B., 1397
Lowry, S. F., 577
Lowy, D. R., 19, 1425, 1584
Lu, J.-J., 1623
Lu, X.-S., 691
Lubin, I., 25
Lucas, S. B., 543
Lundblad, R., 152
Lutwick, L. I., 1423
Lutwick, S. M., 1423
Luukkainen, R., 1290
Mabey, D. C. W., 268
MacLean, S. K., 905
Madigan, J. E., 1141
Maier, E., 1598
Maizels, R. M., 1567
Major, C., 1375
Mäkelä, P. H., 1268
Makhene, M., 1445
Makino, M., 1405
Malawista, S. E., 511
Malinverni, R., 593
Malisa, M. A., 1469
Maloney, E. M., 867
Maloney, S. A., 993
Mandal, B. K., 629
Mandrell, R. E., 1279
Mann, B. J., 1055
Mann, D., 867
Mannhalter, J. W., 1598
Manning, M. C., 1103
Manns, A., 867
Manos, M. M., 895, 1425
Mansfield, K. G., 1149
Manson, J. E., 706
Marchou, B., 258
Margolis, N. H., 308
Marinos, N. J., 232
Marks, A., 1145
Marley, S. E., 1630
Marrakchi-Benjaafar, S., 1312
Marrs, C. F., 1536
Martin, D. H., 446
Martin, L. N., 535
Martinez-Marcos, F. J., 581
Martini, A., 323
Marty, P., 323
Marvin, A. P., 119
Mascart-Lemone, F., 551, 1253
Mascola, J. R., 1636
Maskrey, J. L., 539
Mason, E. O., Jr., 1001
Massarella, J. W., 1475
Mast, E. E., 1122
Matheson, P. B., 353
Matson, D. O., 723, 1437
Matud, J. L., 329
May, T., 656
Mayers, D. L., 1091
McCarthy, J. S., 521
McCracken, G. H., 805
McCutchan, J. A., 902
McElroy, P. D., 1047
McFarland, L. M., 246
McGarry, M. W., 1157
McGowan, J. E., Jr., 1542
McGraw, P. A., 410
McKinney, N., 851
McKnight, B., 11
McLaughlin, J., 1375
McLaughlin, M. M., 1379
McNeil, J. G., 1636
McQueen, P. W., 1384
Mehendale, S. M., 1486
Meignier, B., 250
Meijer, D. K. F., 380
Meissner, J. D., 895
Mekalanos, J. J., 1126
Melcher, G. P., 79
Menegus, M., 389
Menzies, B. E., 410
Merien, F., 281
Merigan, T. C., 70
Merrifield, C., 566
Merrill, D. P., 88
Merriweather, A., 1414
Mertelsmann, R., 610
Meshulam, T., 1153
Meurice, F., 1324
Mevissen, M. L. C. M., 144
Meyer, H.-G. W., 1509
Meyer-König, U., 365
Meyrick, B. O., 1119
Michalski, J., 883
Michels, K. R., 239
Miedema, F., 97
Mileno, M. D., 308
Miller, G., 1367
Miller, R. F., 1087
Miller, R. N., 124
Miner, R. C., 239
Minkoff, H., 235
Mintz, E. D., 1401
Miörner, H., 301, 904
Mishkin, E. M., 1108
Mitchell, D. K., 1437
Mitchell, P. D., 1007
Mitchell, T. J., 119
Miwa, K., 558

Miyagi, T., 220
Miyoshi, I., 220
Mizokami, M., 934
Mkandwire, P. K., 543
Modrow, S., 1356
Moeng, S., 764
Mohr, J. R., 964
Moldawer, L. L., 577
Molitor, T. W., 1137
Möller, L. V. M., 1388
Monath, T. P., 161
Moncada, J., 1411
Mongiardo, N., 105
Monini, P., 1605
Monroe, S. S., 1437
Montagnier, L., 672
Montecalvo, M., 993
Moore, R. D., 346
Morais, P., 867
Morales, M. A. G., 211
Moran, M. A., 785
Mordes, J. P., 974
Moreno, F., 427
Morgan, D., 1401
Morishita, N., 220
Moroni, M., 901, 1595
Morris, P. E., 1119
Morrison, D. C., 1519
Morrow, A. L., 723
Morse, G., 1480
Moser, C. A., 870
Moses, S., 1461
Mosley, J. W., 648
Moss, G. B., 1469
Moynier, M., 672
Mullican, J., 1212
Muñoz, N., 19
Murphy, B. R., 1445
Murray, E. A., 59
Murray, H. W., 1627
Musiani, M., 1360
Mussini, C., 105
Myers, M. G., 944
Myint, K. S. A., 927
Nagai, H., 1554
Naides, S. J., 1198
Nakashima, K., 1098
Nataro, J. P., 883
Navas, E. L., 1528
Nawaz, T., 1480
Nazareno, L. A., 1475
Ndinya-Achola, J. O., 1461, 1469
Nduati, R. W., 1461
Neild, P., 1087
Nelson, B. J., 144
Nelson, S., 1061
Nerng-Ho, H., 329
Nettip, N., 1405
Newell, M.-L., 1418
Newman, F. K., 1, 1445
New York City Perinatal HIV Transmission Collaborative Study Group, 353
Ngai, A., 217
Nicolau, D. P., 810
Niederman, J., 1367
Nielsen, K., 359
Niesters, H. G. M., 38
Nieuwenhuis, T. J., 1475
Nightingale, C. H., 810
Nilehn, B., 682
Nilsson, A., 296
Niphuis, H., 957
Nisenbaum, R., 1184
Njogu, A. R., 845
Nkengasong, J., 1228
Nonnenmacher, B., 19, 1425
Noriega, F. R., 1408
Norkrans, G., 1343
North, R. J., 1550
Notkins, A. L., 232
Nutman, T. B., 831
Nyambi, P. N., 1228
Nyasulu, S., 543
O'Brien, E. R., 585
O'Brien, J., 340
O'Brien, T. R., 1084
Obrig, T. G., 1397
Oei, C., 964
Offit, P. A., 870, 874
Ohl, C. A., 794
Ohtsuki, Y., 220
Ojo-Amaize, E., 1364
Okajima, Y., 558
Olmari, M., 225
Oloo, A. J., 1047
Olsen, K., 805
Olson, R. D., 1317
Ong, C.-K., 895
Onyango, F., 1461
Onyango, F. K., 1047
Onyeji, C. O., 810
Operskalski, E. A., 648
Opstad, N. L., 566
Orlando, G., 1623
Ortolani, C., 105
O'Ryan, M., 723
O'Shaughnessy, M. V., 1375
Osio, M., 1595
Oster, C. N., 1047
Osterhaus, A. D. M. E., 38
O'Toole, C. M., 897
Ottesen, E. A., 521
Otto, E. E., 1
Ottolini, M. G., 243
Oudens, E., 1013
Overbaugh, J., 1461, 1469
Owen, R. J., 1130
Oz, H. S., 506, 1042
Pachón, J., 581
Padian, N. S., 1013, 1084
Pain, P., 1171, 607
Painter, G., 1238
Palenque, E., 608
Palin, K., 1536
Pallansch, M. A., 1206
Pancholi, P., 1007
Panicali, D. L., 329
Paranjape, R. S., 1486
Pardi, D., 554
Paredes, W., 831
Paris, M. M., 805
Parravicini, C., 1595
Parrish, C., 1542
Parry, J. V., 543
Partaledis, J. A., 1238
Partono, F., 1567
Pate, E., 867
Patey, O., 656
Pathey, O., 691
Patnaik, M., 1364
Paton, J. C., 119, 805
Patterson, J. E., 427
Patton, D. L., 585
Paul, J., 983
Paul, W. S., 470
Pauley, D., 1149
Pauwels, R., 380
Pazhanisamy, S., 1238
Pearson, R. D., 1055
Pecharatana, S., 268
Peeters, M., 551, 957, 1228
Peltz, G., 1290
Penne, G., 957
Penny, R., 1384
Peracaula, R., 1172
Perolat, P., 281
Perrin, L., 225
Persing, D. H., 1007
Pertowski, C. A., 817
Peter, J. B., 1364
Peters, C. J., 729, 1166, 1581
Peterson, P. K., 1137
Petri, W. A., Jr., 1055
Pettinelli, C. P., 1246
Peyton, C. L., 895
Pezzotti, P., 1503
Pfaller, M. A., 772
Pfister, H.-W., 113
Phillips, A. N., 1503
Philpott, D. J., 136, 1393
Piacente, P., 1108
Piazza, F. M., 243
Pickering, L. K., 723, 1437
Pickett, M. A., 268
Picot, N., 258
Pietrobon, P. J. F., 1103
Piglia, L., 964
Pikaar, J. C., 481
Piketty, C., 611
Pillot, J., 691
Pineda, M., 1542
Pinzger, G., 395
Piot, P., 1228, 1371
Pipkorn, R., 682
Pitrak, D. L., 312
Pittsburgh Diabetes Research Group, 1206
Pizov, G., 25
Pizzo, P. A., 638, 1028
Plaisier, A. P., 204
Platt, R., 706
Plazzi, M., 1360
Plourde, P. J., 900
Plummer, F. A., 1419, 1469
Pocidalo, J.-J., 1312
Polderman, A. M., 1336
Pollack, M., 794
Pönnighaus, J. M., 543
Pont, J., 1356
Pope, J. H., 919
Popek, E. J., 1451
Popovic, T., 173
Porter, D. J. T., 1238
Portús, M., 323
Post, J. C., 1348
Potts, B. J., 539
Powderly, W. G., 527
Powers, D. C., 1, 1103
Pozio, E., 211
Pratlong, F., 323
Pratt, R. D., 851
Prazuck, T., 691
Preston, F. M., 919
Preston, R. A., 1348
Pribble, J. P., 577
Prince, G. A., 243
Prince, R. A., 599
Prins, J. M., 886
Prop, J., 879
Puchhammer-Stöckl, E., 1356
Purcell, R. H., 31
Putney, S. D., 785
Quarles, J. M., 253
Queener, S. F., 1623
Quiceno, J. I., 951
Quinn, T. C., 1486
Quint, W. G. V., 1298
Raffanti, S., 1167
Raffi, F., 656
Rahija, R. J., 531
Rajan, T. V., 974
Ramsey, K. H., 186
Rand, W., 1160
Rapola, J., 574
Ratnam, S., 1393, 1591
Rausch, D. M., 59
Read, S. E., 1375
Rebollo, M. J., 608
Reed, K. D., 1007
Rees, J. H., 605
Reeves, W. C., 1184
Regelink, A. G., 1388
Regnery, R., 1145
Reichman, R. C., 1480
Reilly, M., 1469
Reisinger, K., 217
Reisner, Y., 25
Remme, H., 204
Reusser, P., 939
Reynes, J., 323
Rezza, G. for the Italian Seroconversion Study, 1503
Rich, E. A., 859
Rich, K. C., 1221

Richardson, B. A., 1461
Richman, D. D., 346, 1246, 1379
Richter, P. J., Jr., 1141
Rindos, P., 1616
Rioux, J. A., 323
Rippy, M. K., 31
Risbud, A. R., 1486
Ritz, A. L., 51
Rivkind, A., 25
Robbins, K. E., 470
Roberts, E. D., 535
Roberts, R. L., 1492
Roblin, P. M., 265
Rocha, E., 1352
Rocourt, J., 277
Rode, C., 1536
Rodrigue, D. C., 1122
Rodrigues, J. J., 1486
Rogers, M. F., 353
Roholl, P. J. M., 38
Roilides, E., 1028
Rojas, J. M., 1602
Roll, M., 296
Rollin, P., 1581
Rollin, P. E., 729
Rompalo, A. E., 1486
Ronald, A. R., 900
Rönnberg, P.-R., 1268, 1273
Rooney, J. F., 232
Roos, M., 97
Rothstein, E., 217
Roumillat, L. F., 1352
Rowen, J. L., 420
Rozdzinski, E., 785
Rubins, J. B., 566
Rudensky, B., 1165
Ruiz, A., 756
Ruiz, N. M., 1091
Rungby, J., 497
Rupp, M. E., 1509
Rusnak, J. M., 906
Russell, W. C., 1421
Russo, T. A., 440
RV43 Study Group, 1091
Rydberg, J., 301
Rydman, R. J., 1221
Saarinen, L., 1268
Saarloos, M.-N., 1095
Saba, J., 656
Sadeghi, H. M., 547
Sadoff, J. C., 180, 1126
Safrin, S., 603
Sagot, N., 672
Sahai, J., 1635
Saikku, P., 1330
St. Louis, M. E., 1584
Saito, K., 638
Salaun, J., 258
Salmon-Ceron, D., 656
Salomon, H., 258
Samorodin, R., 1445
Samuels, N., 1165
Sánchez-Palomino, S., 1602
Santana, M., 1602
Sarai, A., 863
Sarman, G., 1001
Sartono, E., 1567, 1640
Sasaki, Y., 1306
Sathe, S. S., 863
Sauerwein, R. W., 433, 608
Sawada, T., 220
Scalise, G., 1169
Schachter, J., 265, 1013, 1411
Schaeffer, A. J., 1528
Schaffner, A., 1035
Schaffner, M., 1035
Schalkwijk, C., 305
Scharein, E., 606
Schiff, E. R., 648
Schiffman, M. H., 1425
Schiller, J. T., 19, 1425, 1584
Schlager, T. A., 772
Schleiss, M. R., 944
Schlievert, P. M., 1112
Schmader, K., 531
Schmaljohn, A., 1581
Schmaljohn, C., 1581
Schneider, H., 180, 186
Schoen, R. T., 1324
Schreiber, J. R., 453
Schriefer, M. E., 470
Schut, R. L., 340
Schwartz, D., 656
Scott, D. R., 1425
Segura, R. M., 1172
Sei, S., 638
Sein, T., 1028
Sekizaki, T., 1306
Semba, R. D., 1168
Seroky, J. T., 1348
Serr, A., 365
Seuren, L., 305
Sewell, C. M., 729
Sexton, M. M., 838
Shafer, R. W., 70
Shah, K. V., 19
Shaio, M.-F., 604
Shapiro, J. F., 851
Shapiro, M., 31
Shapiro, M. F., 312
Shapiro, T. A., 1157
Shappell, S. B., 1001
Sharpe, S. A., 1261
Shaw, H., 1411
Shay, D. K., 993
Shearer, G. M., 79
Shearer, W. T., 1451
Shedd, D., 1367
Shelton, S., 805
Sheng, W. S., 1137
Shepherd, M. E., 1486
Sherman, M. E., 1425
Sherman, P. M., 136, 1393
Sherwood, J. A., 1047
Shezen, E., 25
Shouval, D., 25
Shrestha, M. P., 927
Shulman, S. T., 558
Shult, P. A., 1352
Shultz, L. D., 974
Sibley, L. D., 1561
Siegel, J. N., 1221
Silva, J., 1108
Sim, M.-S., 359
Simbercoff, M. S., 312
Simon, F., 1228
Simonsen, L., 729
Simpson, M. L., 340
Singh, A. K., 891
Sisay-Joof, F., 316
Sivakumaran, M., 119
Sjöbring, U., 904
Sjölin, J., 296
Skoner, D. P., 1348
Skurnick, J. H., 1084
Slaoui, M., 944
Slizewicz, B., 672
Sloot, N., 1509
Smith, C. W., 420, 1001
Smith, H., 1261
Smith, J. W., 1623
Smith, P. D., 855
Smulian, A. G., 595
Snippe, H., 562
Snitbhan, R., 927
Soderberg, C., 1290
Söderlund, M., 1431
Sokolovskaya, N., 265
Soman, G., 161
Somasundaran, M., 739
Soni, R., 1393
Souberbielle, B. E., 1421
Spaan, W. J. M., 1431
Spangenberger, S., 45
Spann, C. O., 1184
Speaker, T. J., 870
Spear, G. T., 1095
Spector, S. A., 851, 1246
Speelman, P., 886
Spellerberg, B., 785
Spriggs, D. R., 1126
Staehle, B., 217
Staley, T. L., 186
Stamm, W. E., 440, 589
Stanley, C. M., 897
Stanley, J., 1130
Stapleton, A., 440, 772
Starr, S. E., 217
Starzyk, R. M., 785
Steensma, K., 713
Steimer, K. S., 539
Stein, D. K., 511
Steinman, L., 1290
Stern, R. C., 453
Sterne, J. A. C., 543
Stevens, C. E., 648
Stevens, D. A., 1620
Stevens, D. L., 1317
Steward, M. W., 897
Stewart, D.-p., 585
Stewart, G., 831
Stewart, S. K., 638
Stiehm, E. R., 359
Stiles, D. M., 577
Storch, G. A., 527
Stram, D. O., 648
Strathdee, S. A., 1375
Stringer, J. R., 595
Studies of Ocular Complications of AIDS Research Group in collaboration with AIDS Clinical Trials Group, 613
Stull, T. L., 1638
Stutman, H. R., 903
Sule, R. R., 1486
Sullivan, J. L., 739, 974
Summer, W. R., 1061
Sun, B., 713
Sundar, S., 1627
Sundin, D., 246
Suntharasamai, P., 838
Supavej, S., 1405
Sutherland, K., 1130
Suthienkul, O., 1405
Svare, E. I., 1584
Swart, P. J., 380
Syrjälä, H., 1330
Tabarés, E., 1602
Tacket, C. O., 883
Takai, S., 1306
Tallman, P., 1536
Tamaki, H., 739
Tamm, I., 610
Tanaka, S., 934
Tanaka, T., 934
Tanaka, Y., 220
Tang, Y.-W., 734
Tanodi, K., 610
Tapia, R., 246
Tardy, B., 1171, 607
Tarone, R. E., 1425
Tauxe, R. V., 173, 1401
Taylor, D. N., 180, 1126
Tedder, R. S., 1080, 1087
Telford, S. R., III, 1007
Terai, M., 558
ter Meulen, V., 698
Tessier, P. R., 810
Tévi-Bénissan, C., 691
The, T. H., 380, 879
Thea, D. M., 353
Theodos, C., 1160
Thom, B., 1080
Thomas, K., 855
Thomas, P. A., 353
Thomas, W. D., Jr., 161
Thompson, J., 1445
Thoms, W. W., 1184
Thornton, C., 1261
Thorp, J. A., 1076
Thurn, J. R., 566
Tilles, J. G., 1587
Tillikainen, R., 1273
Todd, R. L., 1166
Toé, L., 1414

Tolat, S. N., 1486
Tonawanda/Williamsville Pediatrics, 132
Tongtawe, P., 838
Török, T. J., 1076
Torriani, F. J., 902
Tosi, M. F., 453
Toso, J. F., 964
Tracy, S., 1212
Transfusion Safety Study Group, 648
Tree, T. I. M., 831
Trofa, A. F., 1126
Trombley, C., 293
Tsang, M. L., 1384
Tsarev, S. A., 31
Tsareva, T. S., 31
Tsigler, D., 863
Tso, J. Y., 1317
Tsubaki, S., 1306
Tsukiyama-Kohara, K., 934
Tung, R. D., 1238
Tuomanen, E., 785
Tuppin, P., 672
Turner, A. C., 543
Tweten, R. K., 1317
Tzipori, S., 1160
Uchida, Y., 1306
Uchiyama, T., 1290
Uehling, D. T., 1612
Umland, E. T., 729
Unger, E. R., 1184
Unnasch, T. R., 1414
Urbani, F., 211
Ushijima, H., 403
Vago, L., 901
Vahey, M. T., 1091
Vahlne, A., 1343
van Agtmael, M. A., 886
van Alphen, L., 1388
van Amerongen, G., 38
Van Blaricom, G., 511
van Dalen, R., 433
Vandamme, P., 1298
Van den Borre, C., 1298
van den Bosch, H., 305
Vandenbruaene, M., 551
van den Hoek, J. A. R., 97
van der Bij, W., 879
van der Flier, M., 785
van der Giessen, M., 879
van der Groen, G., 957, 1228
van der Linden, C. J., 608
van der Meer, J. W. M., 305, 433, 608
van der Meer, P., 879
van der Plas, J., 1298
van der Poll, T., 577
VanderVegt, F. P., 232
van der Ven-Jongekrijg, J., 433
van Deuren, M., 433, 608
Van Devanter, N. L., 1084
van Deventer, S. J. H., 144, 886
Van Dyck, E., 1371
van Eerd, P., 957
van Golde, L. M. G., 481
Vanham, G., 957
Van Hove, D., 551
van Iwaarden, J. F., 481
van Lieshout, L., 1336
Van Oortmarssen, G. J., 204
Van Royen, P., 551
van Son, W. J., 879
Van Strijp, J. A. G., 481
Van Voorhis, W. C., 1573
van Zanten, J., 879
Van Zee, K. J., 577
Vargas, S. L., 506
Vartivarian, S. E., 599
Vaughn, D. W., 927
Vazquez-Torres, A., 192
Veasy, L. G., 1608
Vedvick, T., 1055
Veenstra, J., 97
Venegas, M. F., 1528
Venturoli, S., 1360
Verbrugh, H. A., 1423
Vereecken, C., 957
Vereecken, K., 1228
Verheul, A. F. M., 562
Verhoef, J., 481, 562
Vernon, S. D., 1184
Viciana-Fernandez, P., 581
Vildé, J. L., 656
Villa, L. L., 756, 895
Vindimian, M., 607, 1171
Vingerhoets, J., 957
Virolainen, A., 1115
Viscidi, R., 19
Vlaes, L., 1298
Vlahov, D., 1168
Voladri, R. K. R., 410
von der Möhlen, M. A. M., 144
von Laer, D., 365
Von Overbeck, J., 225
von Poblotzki, A., 1356
von Wulffen, H., 606
Voorhout, W. F., 481
Wachsmuth, I. K., 173
Wadström, T., 1135
Wahl, L. M., 794
Wahl, S. M., 855
Waite, J., 1080
Waithaka, H. K., 845
Wakefield, A. E., 506
Walker, B. D., 88
Walsh, T. J., 1028
Walzer, P. D., 595
Wang, C.-L., 604
Wang, S., 585
Wang, T.-H., 261
Ward, B. J., 1591
Ward, M. E., 268
Ward, W., 79
Warndorff, D. K., 543
Warner, T., 192
Wartusch, B., 395
Washburn, R. G., 1023
Wasz-Höckert, O., 574
Watanabe, M., 1191
Watson, B., 217
Watt, P. J., 268
Watts, D. H., 11, 747
Webster, H. K., 838
Webster, R. G., 250
Wedel, N. I., 144
Wei, L. S., 359
Weil, G. J., 521
Weiner, L. B., 389
Weinhold, K. J., 964
Weinstein, R. A., 312
Weiss, L., 547
Weiss, S. H., 51
Welch, M., 1461, 1469
Wells, J. G., 173, 1122, 1401
Weltzin, R., 161
Wenderoth, S., 440
Werner, S. B., 817
Wheeler, A. P., 1119
Wheeler, C. M., 895
Whidden, R., 1411
Whitaker, J. P., 1371
White, A. C., Jr., 1170
White, C. J., 217
White, G. C., III, 228
White, M. L., 144
Whittam, T. S., 772
Whittle, H. C., 316
Wickerts, C.-J., 296
Wideroff, L., 1425
Wijdenes, J., 608
Wiktor, S. Z., 867
Willems, B., 1228
Williams, A., 132
Williams, K., 1475
Williams, T., 558
Wilson, C. C., 88
Wilson, M. H., 1445
Wilson, R. A., 772
Wilson, S., 51
Winters, M. A., 70
Wipf, G. C., 11
Wolf, H., 1356
Wolf, J., 132
Wong, J. T., 88
Wong, K. G., 589
Woo, J., 713
Woodley, C. L., 1542
Wormser, G. P., 993
Wretlind, B., 296
Wright, P. F., 1445
Wysong, D., 511
Xi, L. F., 747
Xing, Y., 1612
Xu, F., 371
Xuan-Thanh, N., 1191
Yang, K. D., 604
Yasui, H., 403
Yazdanbakhsh, M., 1567, 1640
Yeboué, K. M., 1371
Yellin, F. M., 51
Yerly, S., 225
Yinnon, A. M., 1165
Yogev, R., 1475
Young, H. L., 1149
Yu, Y., 371, 531
Yuen, J. B., 389
Yvonnet, B., 258
Zack, P., 31
Zakem-Cloud, H., 453
Zaki, S. R., 1076, 1166
Zaller, D. M., 286
Zangwill, K. M., 570
Zaza, S., 1542
Zehender, G., 1595
Zeimet, A., 395
Zeni, F., 1171, 607
Zerbini, M., 1360
Zerlauth, G., 1598
Zhang, L., 1536
Zhou, S. Y. J., 1091
Zhou, Y., 648
Zimmermann, K., 1598
Ziovudine Epidemiology Study Group, 346
Zollman, T., 1317
Zuckerman, M. A., 1080, 1087
Zurcher, C., 535

Subject Index

21-aminosteroid, for *S. pneumoniae,* meningitis, rat model, 113
α-actin, in infection with attaching and effacing GI pathogens, 1393
α-toxin, *S. aureus,* induction by nafcillin, in vitro, 410
θ-toxin, *C. perfringens,* effect on cardiovascular function, 1317
Acyclovir for
  CMV pneumonia, after autologous marrow transplantation, lack of effect, 939
  HIV infection, use and survival, 346
  HSV infection, resistance, 603
Adenovirus, infection, in HIV infection, 629
Adenovirus type 2 infection, T cell responses, 1421
Adherence, *E. coli,* effect of vaginal fluid on, 1528
AIDS (*See* human immunodeficiency virus type 1 infection)
Amantadine, resistance, of influenza A virus, 1352
Amikacin, for *Staphylococcus* endophthalmitis, 1312
Animal model
  aspergillosis, IFN-γ and TNF-α role in, mouse, 1554
  babesiosis, atovaquone for, hamster, 1042
  B. breve YIT4064, for protection against rotavirus infection, mouse, 403
  C. albicans infection
    cytokine production in, inbred mouse, 823
    nitric oxide effect, on resistance of SCID mouse, 192
  CMV infection
    congenital, guinea pig, 944, 1212
    early-late protein expression, in latent disease, mouse, 371
    reactivation, SCID mouse, 531
  C. parvum infection, *scid* mouse, 1160
  C. pneumoniae lung infection, reactivation by cortisone, mouse, 593
  E. faecalis cytolysin, effect on intestinal growth, mouse, 273
  gram-negative sepsis, cell wall–active antibiotics for, mouse, 1519
  hantavirus infection, macaque, 38
  HCV viremia, chimeric mouse, 25
  HEV infection, pregnant Rhesus monkey, 31
  HIV-1 infection, NOD/LtSz-*scid/scid* mouse, 974
  HIV-1 vaccine, rgp120, mouse, 539
  H. pylori infection, vaccine, mouse, 161
  ICAM-1, role in susceptibility to bacterial infection, ICAM-1–deficient mouse, 1001
  Lyme arthritis
    beige mouse, 778
    human DR4Dw4–transgenic mouse, 286
  measles virus, encephalitis, mouse, 698
  M. tuberculosis, virulence, route of administration effect, mouse, 1550
  parainfluenza type 3 infection, topical immunoglobulin for, cotton rat, 243
  PCP, persistence in lungs, rat, 506
  rotavirus, virus-specific antibody, mouse, 867, 874
  sepsis, gram-negative, cell wall–active antibiotics for, 1519
  SIV infection, effect on CNS, perinatally infected Rhesus monkeys, 59
  S. pneumoniae infection
    immunoglobulin isotype levels and opsonic activity, mouse, 562
    meningitis, rat, 113
Antibody-dependent cellular cytotoxicity
  and neutralizing antibody, in measles, in Filipino children, 1587
  in neutrophils and mononuclear cells, *N*-acetylcysteine effect, in HIV infection, 1492
Antibody
  B. malayi, after diethylcarbamazine therapy, 1567
  CMV, maternal, congenital effect, 944
EBV capsid component, 1367
endotoxin, E5, for sepsis, 152
HEV, preexisting, in pregnant Rhesus monkey model, 31
HHV-6 early antigen (p41/38), 1364
HIV
  as AIDS predictor, 1375
  IgA and IgG, cervicovaginal immunity, 691
  loss or absence, association with disease progression, 897
  measles-specific ADCC, in Filipino children, 1587
  monoclonal
    anti–IFN-γ, in *C. parvum* infection, 1160
    against HSV infection, passive protection, 1108
    in *Mycobacteria*-endemic population, 543
  neutralizing, in HIV infection, 1228
  N. meningitidis serogroup B capsular polysaccharide, 1279
  $p40^{tax}$ protein, in asymptomatic HTLV-I carriers, 1098
  P. aeruginosa, in cystic fibrosis, opsonic activity, 453
  rotavirus
    after inoculation, mouse model, 867, 874
    maternal, 723
  S. pneumoniae
    in otitis, 1115
    polysaccharide vaccine, in HIV infection, 340
Anti-HIV CD8 lymphocyte activity, in long-term survivors, 329
Arthritis, *Y. enterocolitica,* cellular immune response, 1290
Aspergillus fumigatus infection
  IFN-γ and TNF-α role in, mouse model, 1554
  M-CSF effect on MNC, 1028
Aspergillus species, tetrazolium dye assay, for fungal damage assessment, 1153
Astrovirus, diarrhea, in day care center, outbreak, 1437
Atovaquone, for babesiosis, hamster model, 1042
Autolysin, *S. pneumoniae* type 2, role in pathogenesis, 119

Babesiosis
  atovaquone for, hamster model, 1042
  tick vector, 1007
Bacille Calmette-Guérin, recombinant, vaccine against measles, 698
Bacteremia
  MAC, atypical, in AIDS, 901, 902
  S. pneumoniae, drug-resistant, 427
Bactericidal/permeability-increasing protein, in human endotoxemia, 144
Bartonella henselae, antibody, prevalence in US cats, 1145
Bifidobacterium breve YIT4064, for protection against rotavirus infection, 403
Bordetella pertussis, insertional sequence primers, for *P. cepacia* typing, 293
Borrelia burgdorferi infection
  arthritis, mouse model, 286, 778
  I. dammini role, 1007
  isolation from *P. leucopus,* 462
  in Missouri, 1990–1993, 470
Brugia malayi, infection, antibody in, after diethylcarbamazine, 1567

Campylobacter coli, genotyping, 1130
Campylobacter jejuni, infection, and Guillain-Barré syndrome, anti-ganglioside antibody in, 605, 606
Campylobacter upsaliensis, outbreak, in day care center, relationship among isolates, 1298
Cancer, cervical, HPV-16, serologic response, 19
Candida albicans
  hyphae, neutrophil-mediated killing, 511
  infection

cytokine production in, inbred mouse model, 823
nitric oxide effect on resistance, SCID mouse model, 192
wound, nosocomial, after cardiac surgery, 817
Candida species, infection, fluconazole synergy with monocytes or monocyte-derived macrophages, for killing, 1620
Candidiasis, vaginal, recurrence, association with Lewis blood group antigens, 1616
Capsids, HPV-6, to detect antibodies, in people with genital warts, 11
Cat-scratch disease, in Connecticut, 1992–1993, 570
CD4 cell, in HIV infection, pregnancy-induced immune depression, 1221
CD8 cell, clones, effect on HIV-1 replication, 964
Ceftazidime, endotoxin release, in gram-negative urosepsis, 886
Central nervous system, effect of SIV infection, in perinatally infected Rhesus monkeys, 59
Cervical intraepithelial neoplasia, HPV-16, serologic response, 19
Chancroid, epidemiology, in New Orleans men, 446
Chlamydia pneumoniae
in coronary atherectomy tissue, detection, 585
IgE, antibody, in children with reactive airway disease, 265
infection
lung, cortisone reactivation, mouse model, 593
pneumonia, epidemic, in Finnish hospital, 1330
Chlamydia trachomatis
genotypic variants, in STDs, 1013
infection, noninvasive diagnostic tests, 1411
MOMP sequence conservation, 589
ompl gene, genetic change, in Gambian villages, 268
Cholera
epidemic, in Western Hemisphere, 173
V. cholerae O139 Bengal, outbreak among SE Asian tourists, 1401
Chronic fatigue syndrome, IgM antibody to HHV-6 early antigen (p41/38) in, 1364
Clindamycin-quinine, for babesiosis, hamster model, 1042
Clostridium perfringens, exotoxins, effect on cardiovascular function, 1317
Coccidioides immitis, oxidative response to, 199
Cryptococcus neoformans infection
antifungal activity of monocytes and lymphocytes, effect of HIV-1 infection, 665
in HIV-1 infection, NK cell activity, 1023
Cryptosporidium parvum
infection, acute phase, as drug testing model, *scid* mouse, 1160
preparations, effect on proliferation of PBMC in vitro, 211
Cryptosporidium species, infection, paromomycin for, 1169, 1170
Ctenocephalides felis, association with *B. henselae* and cats, 1145
Cystic fibrosis
antibody to *P. aeruginosa* in, opsonic activity, 453
H. influenzae in respiratory tract, multiple strains, 1388
Cystitis, *E. coli,* virulence factors, 772
Cytokines
gene expression, stimulated by coagulation, 308
in inflammation and immunity, a review, 1573
in meningococcal infection, relation to disease severity, 433
modulation by siderophores, 490
and PAF, in Dengue virus infections, 604
plasma levels, in primary septic shock, 296
production in
C. albicans infection, 823
N. gonorrhoeae infection, 186
release, in endotoxemia, BPI effect on, 144
in sepsis, 1171, 1172
Cytolysin, *E. faecalis,* effect on intestinal growth, mouse model, 273
Cytomegalovirus infection
congenital, guinea pig model, 944, 1212
early-late protein expression, in latent infection, mouse, 371
encephalitis, in AIDS, diagnosis, 527
gastrointestinal, foscarnet and ganciclovir for, 622
leukocyte infection, 365
pneumonia, after autologous marrow transplantation, prophylactic acyclovir for, 939
proteins, T cell responses, in transplant recipients, 879
reactivation, SCID mouse model, 531
replication, lactoferrin activity against, in vitro, 380
retinitis, in HIV infection, foscarnet and ganciclovir for, 613, 951
in transplant recipients, PCR for detection, 1641
UL97 mutations, related to ganciclovir resistance, 239
Cytotoxin, *H. pylori,* genetic diversity in, 290

Dapsone, for *P. carinii* pneumonia, in HIV-1 infection, vs. pentamidine, 656
Delayed-type hypersensitivity testing, as predictor in HIV-1 infection, 79
Dengue virus, infection, cytokines and PAF in, 604
Desferoxamine, effect on cytokine production, in murine bone marrow macrophages, 490
Dexamethasone, effect on TSST-1, 988
Diabetes mellitus, onset, association with enteroviruses, 1206
Diarrhea
adenovirus, in HIV infection, 629
rotavirus, detection in feces of children, 45
V. cholerae O139, vaccine against, 883
Didanosine for HIV infection
vs. Ro 24–7429, 1246
and zidovudine, resistance, 70, 1480
Diethylcarbamazine for
B. malayi infection, antibody after chemotherapy, 1567
W. bancrofti infection, 521
Direct sequence analysis, to investigate HBV transmission, 1080
DNA, maxicircle, in *Leishmania* species, 891
DNA-binding assay, to detect antibody to EBV capsid component, 1367

E5, anti-endotoxin antibody, for sepsis, 152
Ehrlichia equi, and human granulocytic ehrlichiosis, in horses, 1141
Ehrlichia species, transmission, 1007
Electron microscopy, to detect group C rotavirus, 45
ELISA
to assess antivirion response, in women, 19
to detect group C rotavirus, 45
Encephalitis
CMV, in AIDS, diagnosis, 527
measles virus, mouse model, 698
Encephalopathy, HIV, virus burden and quinolic acid, 638
Endophthalmitis, *Staphylococcus,* antibiotics for, comparative efficacy, 1312
Endotoxemia. BPI protein, effect on cytokine release and neutrophil activation, in human endotoxemia, 144
Endotoxin
in primary septic shock, 296
release, antibiotic-induced, in gram-negative urosepsis, 886
Enterococcal infections, bloodstream, vancomycin-resistant, epidemiology and mortality risk, 993
Enterococcus faecalis, cytolysin, effect on intestinal growth, mouse model, 273
Enteroviruses, serologic association with onset of diabetes mellitus, 1206
Epidemiology
astrovirus diarrhea, in day care center, outbreak, 1437
B. burgdorferi infection, in Missouri, 1990–1993, 470
B. henselae antibody, prevalence, in US cats, 1145

cat-scratch disease, in Connecticut, 1992–1993, 570
chancroid, in New Orleans men, 446
cholera, epidemic, in Western Hemisphere, 173
C. pneumoniae pneumonia, etiology of epidemic, in Finnish hospital, 1330
C. trachomatis, omp1 gene, genetic change, in Gambia, 268
C. upsaliensis, relationship among isolates, in day care center outbreak, 1298
E. coli O157:H7 infection, cause and course, 1122
enterococcal bloodstream infections, vancomycin-resistant, mortality risk, 993
GAS infection, cyclical peaking, trends, 1165
hantavirus
infection, US outbreak, 729
pulmonary syndrome, risk factors, 1166
HBV transmission, in health care setting, 1080
H. ducreyi, genital ulcers, epidemiology, in New Orleans men, 446
HIV-1 and HTLV-II infection, seroprevalence, in US IVDUs, 51
HIV-1 infection
antenatal zidovudine for, effect on perinatal transmission, 353
incidence
of HPV venereal warts, in women, 235
in India, 1486
infected cells in breast milk, 1461
M. penetrans antibody in, 672
postcoital bleeding, risk in women, 1084
risk group and age as predictors of disease progression, 648
risk in PID, 898, 900
transmission, mother-to-child, in Nairobi, 1418, 1419
HPV infection
cervical, sexual transmission, 756
type 16, seroreactivity in cervical neoplasia, 1425
venereal warts, incidence, in HIV-1–infected women, 235
H. pylori infection, and foreign travel, 1135
HTLV-II, and HIV-1, seroprevalence, in US IVDUs, 51
human granulocytic ehrlichiosis agent, in horses, 1141
influenza type A, outbreaks, summer, 246
Lyme disease, in Missouri, 1990–1993, 470
M. penetrans, antibody, in HIV infection, 672
M. tuberculosis, infection, nosocomial, 1542
parvovirus B19 infection, in hospital workers, 1076
pelvic inflammatory disease, risk for HIV-1 infection, 898, 900
P. falciparum infection, in Kenyan children, 1047
S. pyogenes infection, outbreak, in US Army trainees, 124
varicella, and complications, 706
V. cholerae O139 Bengal infection, outbreak, among SE Asian tourists, 1401
Epstein-Barr virus
capsid antigen complex, antibody to, detection, 1367
infection
cytotoxic T lymphocyte responses, 739
in Simian AIDS, 535
Errata
Beadle et al., 1995;1047–54, 1424
Dropulic et al., 1995;171:930–7, 327
Lorenzl et al., 1995;172:113–8, 1174
Lundblad et al., 1995;172:152–60, 612
North, 1993;168:1059–62, 1424
Patnaik et al., 1995;172:1364–7, 1643
Escherichia coli
adherence, effect of vaginal fluid on, 1528
antibody, and UTI susceptibility, in UTIs in women, 1612
endotoxin-mediated injury, glutathione ethyl ester effect, 1119
O157:H7
infection, outbreak at university, 1122
Shiga-like toxin II, interaction with renal endothelial cells, 1397
phagocytosis, by alveolar macrophages, 481
RDEC-1, signal transduction, 136
sepsis, IL-1 and sTNF receptor in, 577
UTI, recurrent, RFLP analysis of, 440
virulence factors, 772, 1536

Filariasis
lymphatic, diethylcarbamazine for, 521
O. volvulus, cellular and humoral responses, 831
treatment with DEC and PPD of *M. tuberculosis,* 1639, 1640
Fluconazole
for candidiasis, synergy with monocytes or monocyte-derived macrophages, for killing, 1620
effect on zidovudine pharmacokinetics, in HIV infection, 1634, 1635
for fungal infection, prophylactic, during chemotherapy, 1035
for mold infections, high-dose, 599
Foscarnet
for CMV
GI infection, 622
retinitis in AIDS, 613, 951
effect on HIV RNA, 225
Fungal infection, fluconazole prophylaxis for, during chemotherapy, 1035

Ganciclovir
for CMV infection
gastrointestinal, 622
retinitis, in AIDS, 613, 951
UL97 phosphotransferase mutations, in CMV infection, 239
Gastroenteritis, group C rotavirus, in US children, 45
Genital warts, HPV, antibody detection, 11
Glutathione ethyl ester effect, on *E. coli* endotoxin–mediated injury, 1119
Gram-negative sepsis, cell wall–active antibiotics for, 1519
Granulocyte colony-stimulating factor
and GM-CSF, effect on chemiluminescence in neutrophils, by *P. carinii,* 497
role in infectious diseases, review, 1061
Granulocyte-macrophage colony-stimulating factor
activity, against *M. avium–M. intracellulare,* 810
and G-CSF, effect on chemiluminescence in neutrophils, by *P. carinii,* 497
Group A streptococcus infection
class I, in rheumatic fever, 1608
cyclical peaking, 1165
Group B streptococcus, elicits leukotriene B_4 and IL-8, 420
Guillain-Barré syndrome, and *C. jejuni* infection, anti-ganglioside antibody in, 605, 606

Haemophilus ducreyi, genital ulcers, epidemiology, in New Orleans men, 446
Haemophilus influenzae
colonization
nasopharyngeal, in first 2 years of life, 132
in respiratory tract of cystic fibrosis patients, multiple strains, 1388
type b, conjugate vaccine, one-dose immunologic priming, in infancy, 1268
Hantavirus
cross-neutralization, 1581
epidemiology, US outbreak, 729
infection, macaque model, 38
pulmonary syndrome, risk factors, 1166
Helicobacter pylori
cytotoxin, genetic diversity in, 290

infection, and foreign travel, 1135
vaccine, mouse model, 161
Hemagglutinin, *S. epidermidis,* characterization, 1509
Hemophilia, and HIV-1 infection status, 228
Hepatitis B e, seroconversion, nt 1858 mutation, 1343
Hepatitis B virus
infection
atypical, diagnosis, 713
transmission, in health care setting, 1080
vaccine, accelerated vs. classic schedules, 258
X gene and precore region mutations, 1191
Hepatitis C virus
genotypes 1 and 2, kinetics response to IFN-α, 934
infection, coinfection with HIV, progression to AIDS, 1503
quasispecies, hypervariable region, gene drift, in chronic infection, 261
viremia, in SCID→BNX mouse chimera, 25
Hepatitis E virus infection
in pregnant Rhesus monkey model, 31
viremia, humoral responses, 927
Herpes simplex virus
acyclovir-resistant, 603
encephalitis, false-positive PCR, 1641
infection, protection by MAb, 1108
type 1, genetic analysis, 1602
Herpesvirus, DNA, detected by PCR, in HIV infection, 1087
Human granulocytic ehrlichiosis
agent, in horses, 1141
I. dammini role, 1007
Human herpesvirus-6, in CFS, IgM antibody to early antigen (p41/38), 1364
Human immunodeficiency virus type 1
infection
activation of immune cells, 105
acyclovir for, use and survival, 346
ADCC in neutrophils and mononuclear cells, effect of *N*-acetylcysteine, 1492
adenovirus infection in, 629
antenatal zidovudine for, effect on perinatal transmission, 353
antibody, in *Mycobacteria*-endemic population, 543
antibody response, to pneumococcal polysaccharide vaccine, 340
antibody status, association with disease progression, 897
anti-V3 IgG response in, 682
CD4 lymphocyte expansion in, in vitro, 88
CD8 cell clones effect on replication, 964
cervicovaginal immunity, 691
CMV infection in, 527, 613, 622, 951
C. neoformans infection in, NK cell activity in, 1023
coinfection with HCV, progression to AIDS, 1503
didanosine, and zidovudine for, resistance and virologic responses, 70
effect on anticryptococcal activity, of lymphocytes and monocytes, 665
encephalopathy, virus burden and quinolic acid, 638
false-positive PCR, 1420, 1421
foscarnet for, effect on HIV RNA, 225
HIV DNA, association with gonococcal urethritis and CD4 cell depletion, 1469
HIV-specific antibody, as predictor of progression to AIDS, 1375
and HTLV-II, seroprevalence, in US IVDUs, 51
IL-1 production in, 547
immunoglobulin isotype responses in, to pneumococcal polysaccharide vaccine, 1253
incidence of HPV venereal warts, in women, 235
in India, 1486
infected cells in breast milk, 1461
and *Leishmania* species, coinfection, in Mediterranean Basin, 323
MAC infection in, 901, 902, 1598
maternal, fetal death, 1451
modulation of monocytes by IgA, 855
M. penetrans antibody in, 672
neutralizing antibody patterns in, 1228
nevirapine resistance, in patients with >500 CD4 cells/mm^3, 1375
NOD/LtSz-*scid/scid* mouse model, 974
P. carinii pneumonia in, dapsone vs. pentamidine for, 656
PCP in, respiratory burst activation, 497
pediatric, zidovudine resistance in, 359
perinatal, pregnancy-induced immune depression, 1221
postcoital bleeding, risk in women, 1084
pneumococcal vaccination in, 551
predictors of survival, 79
production, effect of smoking on, 859
R. equi virulence in, 1306
risk group and age as predictors of disease progression, 648
risk in PID, 898, 900
RNA and p24 antigen, 1091
Ro 24-7429 vs. zidovudine or didanosine for, 1246
SIV model, 535
S. pneumoniae infection, 566, 983
status and susceptibility of PBMC to infection among hemophiliacs, 228
structure of V3 region, 1384
T cell function, as survival predictor, 97
TMP-SMZ desensitization in, 611
transmission, mother-to-child, in Nairobi, 1418, 1419
virologic characterization, in health care worker, 851
virus burden, in long-term survivors, 329
vitamin A supplementation in, 1167, 1168
VX-478 antiviral therapy for, 1238
zalcitabine for, in children, 1475
zidovudine for, coadministration of azoles, pharmacokinetics, 1634, 1635
zidovudine resistance, after prolonged didanosine therapy, 1480
proteins, immunologic tolerance, in HIV-1 transgenic mice, 232
replication, lactoferrin activity against, in vitro, 380
vaccine
breakthrough infection, 1636, 1637
development of, 1175
rgp120, mouse model, 539
Human papillomavirus
in cervical cancer, disease-free survival, 1184
infection, cervical, sexual transmission, 756
sequence data, 895
venereal warts, incidence, in HIV-1 infected women, 235
Human papillomavirus types 6 and 11
genital warts, 11
virus-like particles, antibody reactivity, in gynecologic patients, 395
Human papillomavirus type 16
seroreactivity in cervical neoplasia, 1425
variants
infection, persistent, 747
serologic cross-reactivity, 1584
virus-like particles, ELISA for, 19
Human T cell lymphotropic virus type I
carrier, asymptomatic, pX mRNA expression in, 1098
HAM/TSP, complement, 1095
T cell subsets, in Jamaican children, 867
Human T cell lymphotropic virus type II
infection, and HIV-1 infection, 51, 1595
regulatory proteins, 554

Human T cell lymphotropic virus types I and II, coinfection, infected cell lines, 220

IgA
effect on HIV-1 infection, 855
response to pneumococcal polysaccharide vaccine, in HIV infection, 1253
IgE, in *C. pneumoniae* infection, in children with reactive airway disease, 265
IgG response
efficacy of subclass, against HSV, 1108
to parvovirus B19 VP1 and VP2, epitope type–specific, 1431
to pneumococcal polysaccharide vaccine, 1253, 1273
IgG4, in *W. bancrofti* infection, 1630
IgM, response to pneumococcal polysaccharide vaccine, in HIV infection, 1253
Imipenem
endotoxin release, in gram-negative urosepsis, 886
for *Staphylococcus* endophthalmitis, 1312
Immunoglobulin
IgA, to pneumococcal polysaccharide vaccine, in HIV infection, 1253
IgG to pneumococcal polysaccharide vaccines, 1253, 1273
IgM, to pneumococcal polysaccharide vaccine, in HIV infection, 1253
topical, for parainfluenza type 3, cotton rat model, 243
Infectious Diseases Society of America
annual meeting information, 907
meeting presentation, HIV vaccine development, 1175
Influenza A virus
cytotoxic T cells, vaccination against, 1
infection
amantadine-resistant, prolonged shedding in immunodeficient patients, 1352
outbreaks, summer, 246
and RSV infections, in hospitalized elderly, 389
and otitis media, 1348
replication, in Vero cells, 250
vaccine, 253, 1103
Intercellular adhesion molecule-1, role in susceptibility to bacterial infection, ICAM-1–deficient mouse model, 1001
Interferon-α, responses to HCV types 1 and 2, in chronic infection, 934
Interferon-γ
in aspergillosis, role in protection against invasive disease, mouse model, 1554
RSV and immunosuppression, 919
for visceral leishmaniasis, 1627
Interleukin-1
production, in HIV infection, effect of zidovudine on, 547
and sTNF receptor, in *E. coli* sepsis, 577
Interleukin-1β, gene expression, stimulated by coagulation, 308
Interleukin-2, role in anticryptococcal activity of NK cell-enriched PBL in HIV-infection, 1023
Interleukin-4, in sepsis, 1171, 1172
Interleukin-6, in sepsis, 607, 608, 1171, 1172
Interleukin-8
in CSF in meningitis, role, 581
and leukotriene B_4, elicited by group B streptococci, 420
levels, to monitor neutropenic patients, 610
in sepsis, 1171, 1172
Interleukin-10
activity, in *P. falciparum* malaria, 838
in sepsis, 1171, 1172
Interleukin-12, vaccine adjuvant, against RSV, 734
Ivermectin, for *O. volvulus* infection, effects, 201
Ixodes dammini, in human granulocytic ehrlichiosis, role, 1007

Kaposi's sarcoma, HSV-like DNA sequences in, 1605
Kawasaki disease, pathogenesis, 558

Lactoferrin, activity, against HIV and CMV replication, in vitro, 380
Leishmania chagasi, antigens, recognition by human lymphocytes, 1055
Leishmania donovani infection
drug cytotoxicity assay, 1157
IFN-γ for, 1627
Leishmania infantum complex, isoenzymatic characterization, for leishmaniasis–HIV-1–infected patients, 323
Leishmania species, identification, by DNA probe, 891
Leptospira species, PCR to diagnose, 281
Leukocyte
adhesion, blockade by peptide, 785
CMV infection, 365
Leukotriene B_4, and IL-8, elicited by group B streptococci, 420
Ligase chain reaction, to diagnose *C. trachomatis* infection, in first-catch urines, 1411
Lipopolysaccharide, monocyte uptake, effect of MAbs on, 794
Listeria species, antibiotic resistance, 277
Lyme disease *(See Borrelia burgdorferi* infection)

Macrolide, activity against *M. avium–M. intracellulare,* 810
Macrophage
alveolar, HIV-1 infection of, 859
in HIV-1 infection, pentoxifylline effect on, 863
Macrophage colony-stimulating factor, in *A. fumigatus* infection, 1028
Major outer membrane protein variants, *C. trachomatis,* in STDs, 1013
Malaria
fever in, genetic regulation of, in Gambian twins, 316
IL-10 activity in, 838
Measles
ADCC and neutralizing antibody, in Filipino children, 1587
encephalitis, mouse model, 698
vaccine, failure, cellular immunity in, 1591
Meningitis
antiinflammatory therapy, 785
IL-8 in CSF, role, 581
S. pneumoniae
21-aminosteroid for, rat model, 113
pneumolysin role in, 805
Minocycline, resistance in *Listeria* species, 277
Mold infections, fluconazole for, 599
MOMP gene, sequence conservation, in *C. trachomatis* urogenital tract infection, 589
Monoclonal antibody, to LPS, effect on monocyte uptake, 794
Monocyte
infection, by HIV-1, 855
neonatal, diminished function, 420
Multilocus enzyme electrophoresis, of *V. cholerae,* 173
Mycobacterial infection, HIV antibody test in presence of, 543
Mycobacterium avium complex infection
bacteremia, atypical, in AIDS, 901, 902
in HIV infection, effect on phagocyte function, 1598
pentoxifylline effect on macrophage defense, 863
in Simian AIDS, 1149
Mycobacterium tuberculosis
infection
diagnosis, PCR, 903, 904
nosocomial, role of health care workers, 1542
PCR to detect, 608
virulence, effect of route of administration, mouse model, 1550
Mycoplasma penetrans, antibody, in HIV infection, 672

N-acetylcysteine, effect on ADCC in neutrophils and mononuclear cells, in HIV infection, 1492
Nafcillin, α-toxin production induced by, in *S. aureus,* 410
Neisseria gonorrhoeae
infection, cytokine response in, 186
infectivity, in urethritis, 180
Neisseria meningitidis
capsular polysaccharide, antibody to, 1279
infection, proinflammatory cytokines and antiinflammatory mediators in, relation to disease severity, 433
Neutrophil
activation, in endotoxemia, BPI effect on, 144
fungicidal activity, against *C. albicans* hyphae, 511
oxidant release from *C. immitis,* 199
Nevirapine, resistance, in HIV infection, in patients with >500 CD4 cells/mm^3, 1375
Nitric oxide, in candidiasis, effect on resistance of SCID mice to *C. albicans,* 192
NK cells, anticryptococcal activity, cytokine role, 1023
Non-A, non-B hepatitis, association with hepatitis B virus, 713

Onchocerca volvulus
cellular and humoral responses, 831
infection
ivermectin effects, 201
prevalence in vectors, by PCR screening of black flies, 1414
Oral hairy leukoplakia, nonhuman primate model for, 535
Osteitis, due to Bacille Calmette-Guérin vaccination, 574
Otitis media
acute, influenza A virus–induced, 1348
H. influenzae, in first 2 years of life, 132
Otitis, *S. pneumoniae,* antibody to, 1115

p24 antigen in
CMV retinitis, 613
HIV infection, relationship to antibody and HIV RNA, 1091
Papillomavirus, human
disease-free survival, in cervical cancer, 1184
sequence data, 895
types 11 and 6, virus-like particles, antibody reactivity, in gynecologic patients, 395
type 16
seroreactivity in cervical neoplasia, 1425
variants, 747, 1584
Parainfluenza type 3 virus
human, vaccine, tested in infants and children, 1445
infection, topical immunoglobulin for, cotton rat model, 243
Paromomycin, for *Cryptosporidium* infection, 1169, 1170
Parvovirus B19
infection
acquisition, in hospital workers, 1076
acute, clearance from peripheral blood, 1360
persistent, antibody to nonstructural protein, 1356
tissue tropism, determinants, 1198
VP1 and VP2, epitope type–specific IgG responses, 1431
Pelvic inflammatory disease, risk for HIV-1 infection, 898, 900
Pentamidine, for *P. carinii* pneumonia, in HIV-1 infection, vs. dapsone, 656
Pentoxifylline, effect on macrophage defense, in MAC infection, 863
Perfloxacin, for *Staphylococcus* endophthalmitis, 1312
Peripheral blood lymphocyte assay, quantitative, for determining resistance in vitro to zidovudine, 359
Peru-15, vaccine against *V. cholerae,* 1126
Phagocytosis, of gram-negative bacteria, by alveolar macrophages, 481
Phospholipase A2, in typhoid fever, is circulating mediator, 305
Phospholipase C, *C. perfringens,* effect on cardiovascular function, 1317
Plaque-reduction neutralization test, in hantavirus infection, 1581
Plasmodium falciparum malaria
epidemiology, in Kenyan children, 1047
fever in, genetic regulation of, in Gambian twins, 316
IL-10 activity in, 838
vaccine trial design, 1047
Platelet-activating factor, in Dengue virus infections, 604
Pneumocystis carinii pneumonia
in HIV infection
dapsone vs. pentamidine for, 656
diagnosis by PCR on sera, 1623
respiratory burst activity, 497
treatment, empirical, 1987–1990, 312
persistence in lungs, rat model, 506
Pneumocystis carinii hominis, pneumonia, recurrent, genetic variation, 595
Pneumolysin
in pneumococcal meningitis, role, 805
S. pneumoniae type 2, role in pathogenesis, 119
Pneumonia
C. pneumoniae, etiology of epidemic, in Finnish hospital, 1330
P. carinii
in HIV infection, 497, 656, 1623
persistence in lungs, rat model, 506
treatment, empirical, 1987–1990, 312
P. c. hominis, recurrent, genetic variation, 595
S. pneumoniae
in HIV-1 infection, characterization of isolates, 983
type 2, pathogenesis, autolysin and pneumolysin role in, 119
Polyacrylamide gel electrophoresis, analysis of *B. burgdorferi,* 462
Polymerase chain reaction to detect
astrovirus, in stool, 1437
CMV, 365, 527, 1641
C. trachomatis sequence variation, 589
E. equi, 1141
HBV, 1080
herpesvirus DNA, in HIV infection, 1087
HEV, 927
HIV, 638, 1420, 1421, 1469
HSV, in encephalitis, false-positive results, 1641
IL-1β mRNA, in whole blood, 308
influenza A virus, 1352
Leptospira species, vs. microagglutination test and culture, 281
M. tuberculosis, 608, 903, 904
O. volvulus, in pools of black flies, 1414
parvovirus B19, 1356
P. carinii, in pneumonia, in HIV infection, 1623
P. cepacia, 293
T. gondii, in blood, 319
Polymerase chain reaction ribotyping, vs. PFGE, 1638, 1638
Polyneuropathy, predominantly sensory, role of HTLV-II in HIV infection, 1595
Pregnancy, in HIV infection, pregnancy-induced immune depression, 1221
Pseudomonas aeruginosa, antibody, in cystic fibrosis, opsonic activity, 453
Pseudomonas cepacia, typing methods, 293

Quinolic acid, in HIV encephalopathy, 638
Quinolone, activity against *M. avium–M. intracellulare,* 810

Respiratory syncytial virus
IL-12 vaccine, adjuvant for, 734
immunosuppressive factor, 919

infection, and influenza A infections, in hospitalized elderly, 389
Restriction fragment length polymorphism analysis
C. coli, 1130
E. coli, in recurrent UTIs, 440
Retinitis, CMV, in AIDS, ganciclovir and foscarnet for, 951
Reverse transcriptase–polymerase chain reaction, to detect group C rotavirus, 45
Review, cytokines, in inflammation and immunity, 1573
RexII, and TaxII, HTLV-I regulatory proteins, 554
Rheumatic fever, GAS class I infection in, 1608
Rhodococcus equi, virulence-associated antigens and plasmids, in AIDS, 1306
Ro 24-7429, vs. zidovudine or didanosine, for HIV infection, activity and safety, 1246
Rotavirus
immunization, maternal, effect on milk and serum antibody titers, 723
induction of virus-specific antibody, after intramuscular inoculation, mouse model, 867, 874

Schistosoma mansoni, infection, worm burden variation and antigen concentrations, 1336
Sepsis
E. coli, IL-1 and sTNF receptor in, 577
fulminant, E5, imipenem, and volume support, synergistic effect, 152
gram-negative, cell wall–active antibiotics for, 1519
sIL-6 receptor in, 607, 608
Septic shock, primary, cytokine plasma levels in, 296
Sexually transmitted disease, in Haitian pregnant women, 764
Shiga-like toxin II, *E. coli* O157:H7, interaction with renal endothelial cells, 1397
Shigella, enterotoxin 1, prevalence among clinical isolates of diverse serotypes, 1408
Simian immunodeficiency virus
cellular immunity in, chimpanzee, 957
effect on CNS, in perinatally infected Rhesus monkeys, 59
MAC infection in, 1149
MHC class II antigen, constitutive expression of, 1261
rhesus EBV infection in, 535
Sin nombre virus, hantavirus pulmonary syndrome, 729
Sparfloxacin, for *Staphylococcus* endophthalmitis, 1312
Staphylococcal toxins, in Kawasaki disease, 558
Staphylococcus, endophthalmitis, antibiotics for, comparative efficacy, 1312
Staphylococcus aureus
α-toxin, induced in vitro by growth of *S. aureus* with nafcillin, 410
colonization, relation to wound infection after cardiac surgery, 1423
TSST, effect of tampons, 1112
Staphylococcus epidermidis, hemagglutinin, characterization, 1509
Streptococcus pneumoniae infection
bacteremia
drug-resistant, 427
in HIV infection, 566
immunoglobulin isotype levels and opsonic activity, mouse model, 562
meningitis
21-aminosteroid for, rat model, 113
pneumolysin role in, 805
otitis, antibody to, 1115
pneumonia, in HIV-1 infection, characterization of isolates, 983
polysaccharide, vaccine against, antibody response, in HIV infection, 340
type 2, pneumonia and septicemia, pneumolysin and autolysin role in, 119
vaccine, 551, 1273
Streptococcus pyogenes, infection, outbreak, in US Army trainees, 124
Streptomycin, resistance in *Listeria* species, 277
Surfactant proteins A and D, phagocytosis, 481
Syphilis, false-positive RPR tests and anti-cardiolipin antibody, 905, 906

Tampons, effect on *S. aureus* TSST, 1112
T cell
activation, massive, in HIV-1 infection, 105
CD4, in vitro expansion, in HIV infection, 88
CD4CD29 percentage, as predictor in HIV-1 infection, 79
cytotoxic, response to
EBV infection, 739
influenza A vaccine, in elderly, 1103
function, as predictor, in HIV-1 infection, 79, 97
proliferative, to polypeptides from adenovirus type 2, 1421
response, to CMV proteins, in transplant recipients, 879
subsets, in HTLV-I infection, in Jamaican children, 867
Tetracycline, resistance in *Listeria* species, 277
Tetrazolium dye assay, for fungal damage assessment, 1153
Thalidomide, effect on TNF production, by human microglial cells, 1137
Thrombosis, inflammation due to IL-1β synthesis, 308
Toxic shock syndrome toxin, *S. aureus,* effect of tampons, 1112
Toxic shock syndrome toxin-1, induced cytokine production, effect of IL-10 and dexamethasone, 988
Toxoplasma gondii
clonal lineages, correlation with human disease, 1561
infection, PCR for diagnosis, in blood, 319
Trachoma, *C. trachomatis ompl* gene, genetic change, in Gambian villages, 268
Treponema pallidum, infection, false-positive RPR tests and anti-cardiolipin antibody, 905, 906
Trimethoprim, resistance in *Listeria* species, 277
Trimethoprim-sulfamethoxazole, for HIV infection, desensitization in, 611
Tropical spastic paraparesis, complement fragments, 1095
Trypanosoma brucei, infection, drug cytotoxicity assay, 1157
Trypanosomiasis, vaccine against, 845
Tumor necrosis factor
in sepsis, 1171, 1172
soluble receptors, in *E. coli* sepsis, 577
and sTNFR forms, relationship in tuberculous infection of CNS, 301
Tumor necrosis factor-α
in aspergillosis, role in protection against invasive disease, mouse model, 1554
LPS-induced, effect of MAbs on, 794
production, by human microglial cells, thalidomide effect on, 1137
Typhoid fever, phospholipase A2 is circulating mediator, 305

Urethritis, *N. gonorrhoeae*
in HIV infection, 1469
infectivity, 180
Urinary tract infection due to *E. coli*
adherence in, effect of vaginal fluid on, 1528
antibody and UTI susceptibility, in women, 1612
recurrent, RFLP analysis of, 440
virulence factors, as predictor of second UTI, 1536
Urosepsis, gram-negative, antibiotic-induced endotoxin release in, 886

Vaccine against
CMV, congenital infection after maternal immunization, 1212
HBV, accelerated vs. classic schedules, 258
H. influenzae, type b, conjugate, one-dose immunologic priming, in infancy, 1268
HIV, 539, 1175, 1636, 1637

HPV-3, safety, immunogenicity, infectivity, and phenotypic stability, in children, 1445
H. pylori, mouse model, 161
influenza, trivalent cold-adapted recombinant, 253
influenza A, in elderly, 1, 1103
measles, cellular immunity role in failure, 1591
OspA, in subjects with previous Lyme disease, safety and immunogenicity, 1324
P. falciparum, trial design, 1047
RSV, IL-12, 734
S. pneumoniae
in HIV infection, antibody response, 551
polysaccharide, immune responses, 340, 1253, 1273
trypanosomiasis, 845
varicella, booster, safety and cellular and immune responses, 217
V. cholerae, 883, 1126
Vancomycin
resistance, in enterococcal bloodstream infections, epidemiology and mortality risk, 993
for *Staphylococcus* endophthalmitis, 1312
Varicella, vaccine, booster, safety and cellular and immune responses, 217
Varicella-zoster virus, infection, and complications, epidemiology, 706
Vibrio cholerae
multilocus enzyme electrophoresis, 173
O139
infection, among SE Asian tourists, 1401
vaccine against, 883, 1126
Vibrio parahaemolyticus, *trh* gene, correlation with urease production, 1405
Virulence
E. coli, in UTI, as predictor of second UTI, 1536
M. tuberculosis, effect of route of administration, mouse model, 1550
Virus-like particles, HPV-6 and -11, for detection of type-specific antibodies, 395
Vitamin A, supplementation, in AIDS, 1167, 1168
VX-478, for HIV infection, binding to plasma proteins, 1238

Wound infection
C. albicans, nosocomial, after cardiac surgery, 817
S. aureus, 1423
Wucheria bancrofti infection
diethylcarbamazine for, 521
IgG4 response, 1630

X gene, in HBV genome, 1191

Yersinia enterocolitica
arthritis, cellular immune response, 1290
siderophore production by, 490

Zalcitabine, for HIV infection, in children, 1475
Zidovudine
for HIV infection
acyclovir use, 346
antenatal, effect on perinatal transmission, 353
coadministration of azoles, pharmacokinetics, 1634, 1635
and didanosine, resistance and virologic responses, 70
effect on IL-1 production, 547
pre-AIDS use, effect on survival, 97
resistance, 359, 1480
vs. Ro 24–7429, 1246
for SIV infection, effect on CNS, of perinatally infected Rhesus monkeys, 59